Your browser doesn't support javascript.
loading
Repetitive Transcranial Magnetic Stimulation for Tobacco Treatment in Cancer Patients: A Preliminary Report of a One-Week Treatment.
Li, Xingbao; Toll, Benjamin A; Carpenter, Matthew J; Nietert, Paul J; Dancy, Morgan; George, Mark S.
Afiliación
  • Li X; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
  • Toll BA; Center for Biomedical Imaging, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
  • Carpenter MJ; Hollings Cancer Center Medical University of South Carolina, USA.
  • Nietert PJ; Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
  • Dancy M; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
  • George MS; Hollings Cancer Center Medical University of South Carolina, USA.
J Smok Cessat ; 2022: 2617146, 2022.
Article en En | MEDLINE | ID: mdl-35909440
ABSTRACT

Background:

Smoking cessation represents a significant opportunity to improve cancer survival rates, reduces the risk of cancer treatment complications, and improves quality of life. However, about half of cancer patients who smoke continue to smoke despite the availability of several treatments. Previous studies demonstrate that repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) decreases cue craving, reduces cigarette consumption, and increases the quit rate in tobacco use disorder. We investigated whether 5 sessions of rTMS can be safely and efficaciously used for smoking cessation in cancer patients.

Methods:

We enrolled 11 treatment-seeking smokers with cancer (>5 cigarettes per day) in a randomized, double-blind, sham-controlled proof-of-concept study. Participants received 5 daily sessions of active 10 Hz rTMS of the left DLPFC (3000 pulses per session) or sham rTMS and were followed up for 1 month via phone assessments. Main outcomes included reductions in the number of smoked-cigarettes per day (primary) and craving (secondary). Adverse effects were reported daily by participants.

Results:

Seven of 11 participants completed 5 sessions of rTMS over one week. Compared to sham treatment (n = 4), the active rTMS (n = 3) exhibited modest effects overtime on smoking (Cohen's f 2 effect size of 0.16) and large effects on cue craving (Cohen's f 2 = 0.40). No serious side effects related to rTMS were reported in the treatment.

Conclusions:

Five sessions of daily rTMS over the left DLPFC might benefit cancer patients who smoke cigarettes. However, further evidence is needed to determine with more certainty its therapeutic effect and adverse effects for cancer patients who smoke cigarettes.

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Clinical_trials Idioma: En Revista: J Smok Cessat Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Clinical_trials Idioma: En Revista: J Smok Cessat Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos